



12-23-05

SFW 4

AMENDMENT TRANSMITTAL LETTER

Docket No.
05432/100M919-US5Application No.
10/644,576Filing Date
August 20, 2003Examiner
Y. S. ChongArt Unit
1617

Applicant(s): Connie Sanchez et al.

Invention: THE USE OF ENANTIOMERIC PURE ESCITALOPRAM

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	18	- 20 =		x	
Independent Claims	1	- 3 =		x	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0.00

 Large Entity Small Entity No additional fee is required for this amendment. Please charge Deposit Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed. A check in the amount of \$ _____ to cover the filing fee is enclosed. Payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized to charge and credit Deposit Account No. 04-0100 as described below. Credit any overpayment. Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.Jay P. Lesser
Attorney Reg. No.: 41,151DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7765

Dated: December 23, 2005

RECEIVED
OIPE/IAP

JAN 06 2006

Express Mail Label No.

Dated: _____

Docket No.: 05432/100M919-US5
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Connie Sanchez et al.

Application No.: 10/644,576

Confirmation No.: 5194

Filed: August 20, 2003

Art Unit: 1617

For: THE USE OF ENANTIOMERIC PURE
ESCITALOPRAM

Examiner: Y. S. Chong

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated June 23, 2005, please amend the above-identified U.S. patent application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.